The Orbitex Group of Funds of New York last week introduced the Orbitex Life Sciences & Biotechnology Fund. Orbitex' first interval fund will invest in small- to mid-sized companies in the life sciences, pharmaceuticals, medical research and biotechnology research, development and implementation, the company said.

As an interval fund, it operates as a closed-end fund, but periodically opens up to new investors. There is a minimum investment of $25,000 and a thirty-day subscription period and $100 million cut off point to new investors, according to the company.

Subscribe Now

Access to premium content including in-depth coverage of mutual funds, hedge funds, 401(K)s, 529 plans, and more.

3-Week Free Trial

Insight and analysis into the management, marketing, operations and technology of the asset management industry.